Amarin | AMRN - Ativo Circulante





Ativo Circulante Alterar Data
AbbVie USD 37.48B 3.81B 2026-09
Alnylam Pharmaceuticals USD 5.11B 492.49M 2026-09
Amarin USD 612.88M 10.12M 2026-09
AstraZeneca USD 31.45B 3.48B 2026-09
BioCryst Pharmaceuticals USD 531.15M 46.47M 2026-09
DBV Technologies USD 189.6M 12.3M 2026-09
GlaxoSmithKline GBP 17.9B 336M 2026-09
Halozyme Therapeutics USD 1.85B 913.71M 2026-09
Heron Therapeutics USD 209.11M 20.73M 2026-09
Ionis Pharmaceuticals USD 2.36B 129.77M 2026-09
Nektar Therapeutics USD 589.04M 322.77M 2026-03
Neurocrine Biosciences USD 2.01B 370.7M 2026-09
Novartis USD 28.75B 1.4B 2026-09